Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - carglumic acid - amino acid metabolism, inborn errors; propionic acidemia - other alimentary tract and metabolism products, - carbaglu is indicated in treatment of:hyperammonaemia due to n-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - betaine anhydrous - homocystinuria - other alimentary tract and metabolism products, - adjunctive treatment of homocystinuria, involving deficiencies or defects in:cystathionine beta-synthase (cbs);5,10-methylene-tetrahydrofolate reductase (mthfr);cobalamin cofactor metabolism (cbl).cystadane should be used as supplement to other therapies such as vitamin b6 (pyridoxine), vitamin b12 (cobalamin), folate and a specific diet.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - mercaptamine hydrochloride - cystinosis - ophthalmologicals - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - mercaptamine bitartrate - cystinosis - other alimentary tract and metabolism products, - cystagon is indicated for the treatment of proven nephropathic cystinosis. cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - tocofersolan - cholestasis; vitamin e deficiency - vitamins - vedrop is indicated in vitamin-e deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - zinc - hepatolenticular degeneration - other alimentary tract and metabolism products, - treatment of wilson's disease.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - ibuprofen - ductus arteriosus, patent - cardiac therapy - treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati ireland ltd. - lidocaine, prilocaine - sexual dysfunction, physiological - anesthetics - treatment of primary premature ejaculation in adult men.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - pasireotide - acromegaly; pituitary acth hypersecretion - pituitary and hypothalamic hormones and analogues - signifor is indicated for the treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

Euroopa Liit - inglise - EMA (European Medicines Agency)

recordati rare diseases - osilodrostat phosphate - cushing syndrome - corticosteroids for systemic use - isturisa is indicated for the treatment of endogenous cushing’s syndrome in adults.